Szerző: " Shimura Masahiko"

Danzig Carl J; Dinah Christiana; Ghanchi Faruque; Hattenbach Lars-Olof; Khanani Arshad M; Lai Timothy Y Y; Shimura Masahiko; Abreu Francis; Arrisi Pablo; Liu Ying; Paris Liliana P; Retiere Anne-Cecile; Willis Jeffrey R; Schlottmann Patricio G; Tóth-Molnár Edit: Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. 72-Week Results from the BALATON and COMINO Trials.
OPHTHALMOLOGY RETINA, 9 (9). pp. 848-859. ISSN 2468-6530 (2025)

Suzuma Kiyoshi; Murata Toshinori; Shimura Masahiko; Yoshida Shigeo; Kishino Genichiro; Berliner Alyson J; Chu Karen W; Reed Kimberly; Vitti Robert; Cheng Yenchieh; Voronca Delia; Bhore Rafia; Leal Sergio; Morgan-Warren Peter; Schulze Andrea; Schmidt-Ott Ursula; Kobayashi Masato; Sakamoto Taiji; Kollaborációs szervezet PHOTON Investigators; Tóth-Molnár Edit; et al.: Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema : 48-week subgroup analysis of the PHOTON trial.
JAPANESE JOURNAL OF OPHTHALMOLOGY. ISSN 0021-5155 (2025)

Shimura Masahiko; Kitano Shigehiko; Ogata Nahoko; Mitamura Yoshinori; Oh Hideyasu; Kollaborációs szervezet: YOSEMITE and RHINE Investigators; Bátor György; Seres András; Szalczer Lajos; Tóth-Molnár Edit; Vajas Attila; Varsány Balázs; Kerény Ágnes; Papp András; Szecskó Tímea; Vogt Gábor: Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial.
JAPANESE JOURNAL OF OPHTHALMOLOGY, 67 (3). pp. 264-279. ISSN 0021-5155 (2023)